Results 71 to 80 of about 2,870,340 (221)

The Effects of Cyclic Nucleotide Phosphodiesterase Inhibitors on Ejaculated Porcine Spermatozoan Metabolism1 [PDF]

, 1973
David L. Garbers, Neal L. First, Sharon K. Gorman, Henry A. Lardy   +3 more
openalex   +1 more source

Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition

Mediators of Inflammation, 2015
Phosphodiesterase type 5 inhibitors (PDE5-Is) have recently emerged as a potential therapeutic strategy for neuroinflammatory, neurodegenerative, and memory loss diseases.
C. Peixoto, A. Nunes, A. García-Osta
semanticscholar   +1 more source

Cardiac Uses of Phosphodiesterase-5 Inhibitors

Journal of the American College of Cardiology, 2012
Phosphodiesterase-5 inhibitors (PDE5Is) improve erectile function by enhancing nitric oxide availability in the penis and its supplying vasculature, resulting in vasodilation and increased blood flow. PDE5Is might benefit cardiovascular diseases because phosphodiesterase-5 is also located elsewhere in the body, including the pulmonary and systemic ...
Bryan G. Schwartz, Gary Comstock, Vera J. Stecher, Robert A. Kloner, Robert A. Kloner, Laurence A. Levine   +5 more
openaire   +3 more sources

Binding of inhibitor alters kinetic and physical properties of extracellular cyclic AMP phosphodiesterase from Dictyostelium discoideum. [PDF]

, 1979
Richard H. Kessin, Seth J. Orlow, Reneé Shapiro, Jakob Franke   +3 more
openalex   +1 more source

Docking studies: In silico phosphodiesterase inhibitory activity of commercially available flavonoids

Bangladesh Journal of Pharmacology, 2012
The objective of the current study is to evaluate the phosphodiesterase inhibitory activity of flavonoids using in silico docking studies. In silico docking studies were carried out using AutoDock 4.2, based on the Lamarckian genetic algorithm principle.
Arumugam Madeswaran, Muthuswamy Umamaheswari, Kuppusamy Asokkumar, Thirumalaisamy Sivashanmugam, Varadharajan Subhadradevi, Puliyath Jagannath   +5 more
doaj   +1 more source

Use of Phosphodiesterase Inhibitors in the Postoperative Period of Skin Flaps: A Systematic Review. [PDF]

Plast Reconstr Surg Glob Open, 2023
Daronch OT, Marcante RFR, Neto AAP, Viterbo F.   +3 more
europepmc   +1 more source

Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules. [PDF]

Front Pharmacol, 2022
Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Liu W, Schiöth HB.   +6 more
europepmc   +1 more source

Proniosomal Gel-Loaded Phosphodiesterase Inhibitors (Sildenafil, Vardenafil, and Tadalafil): Prospects for Topical Penile Therapy of Tadalafil for Treatment of Erectile Dysfunction. [PDF]

Gels, 2023
Mohamed SA, Rofaeil RR, Salem H, Elrehany M, Asiri YI, Al Fatease A, Abdelkader H.   +6 more
europepmc   +1 more source

Addition of Sildenafil in Patients with Pulmonary Arterial Hypertension with Inadequate Response to Bosentan Monotherapy

Canadian Respiratory Journal, 2008
BACKGROUND: Pulmonary arterial hypertension (PAH) remains a progressive disease despite improvement when using one of three medication classes: prostanoids, endothelin receptor antagonists or phosphodiesterase-5 inhibitors.
Nancy R Porhownik, Hassan Al-Sharif, Zoheir Bshouty   +2 more
doaj   +1 more source

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors. [PDF]

Pharmaceuticals (Basel), 2022
Ovchinnikov A, Potekhina A, Belyavskiy E, Ageev F.   +3 more
europepmc   +1 more source